Skip to main content
. 2023 Jun 21;11(6):e007068. doi: 10.1136/jitc-2023-007068

Figure 6.

Figure 6

CSBP enhances antitumor efficacy combined with RT in the 4T1 tumor model. (A) Treatment schedules and dosing. (B) 4T1 tumor growth following CSBP and/or RT treatment in vivo. Data are presented as the means±SEM (n=5 per group). (C) Flow cytometric analysis of CD8+ T cells on CD45+ cells in each group (n=5). (D) The frequency of IFN-γ-expressing CD8+ T cells was detected by flow cytometry (n=5). (E, F) Quantitative data of the M1/M2 ratio and the percentage of myeloid-derived suppressor cells relative to CD45+ cells in each group (n=5). M1, CD45+ CD11b+ F4/80+ CD11c+ CD206−; M2, CD45+ CD11b+ F4/80+ CD206+ CD11c−; G-MDSC, CD45+ CD11b+ Ly6G+ Ly6C−; M-MDSC, CD45+ CD11b+ Ly6G− Ly6C+. (G, H) Cells from mice draining lymph nodes (G) or spleens (H) were obtained and stimulated with 20 ng/mL of PMA and 1 µM ionomycin containing protein transport inhibitor cocktail for 4 hours. Frequencies of IFN-γ-expressing CD8+ T cells were detected by flow cytometry (n=5). Data are presented as means±SEM, and statistical significance was determined by two-way analysis of variance with multiple comparisons. *p<0.05, **p<0.01, ***p<0.001. CSBP, CD24/Siglec-10 blocking peptide; G-MDSC, granulocytic myeloid-derived suppressor cell; IFN, interferon; i.p., intraperitoneally; M-MDSC, monocytic myeloid-derived suppressor cell; PMA, phorbol 12-myristate 13-acetate; RT, radiotherapy; TME, tumor microenvironment.